Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

UTHR vs TAK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TAK Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)

TAK Overall Winner 6-Pillar Tally: UTHR 2 – 4 TAK Matrix Metrics: UTHR 4 – 6 TAK

As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over United Therapeutics Corp (UTHR) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). UTHR carries a Unified Composite Score of 44.8/100 (HOLD) at $584.19 (18.8x Forward P/E, 39.4% operating margin), whereas TAK carries 48.0/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About UTHR vs TAK
UTHR NASDAQ
United Therapeutics Corp
Pharmaceutical Preparations
$584.19
-1.18% 1D
Market Cap $25.3B
TTM Revenue $3.19B
Forward P/E 18.8x
Beta / 30D Vol 0.34β · 34% Vol
Unified Composite Score
44.8 / 100 HOLD
Tech 36.0 Fund 45.0 Flow 68.0 Mom 31.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.8% over 20 days), RSI 55
RSI-14: 54.6 · SMA20: $586.08 · SMA50: $544.53
TAK NYSE Head-to-Head Winner
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Pharmaceutical Preparations
$21.61
+0.86% 1D
Market Cap $67.5B
TTM Revenue $25.7B
Forward P/E 12.7x
Beta / 30D Vol -0.02β · 22% Vol
Unified Composite Score
48.0 / 100 HOLD
Tech 43.0 Fund 44.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.9% over 20 days), RSI 72
RSI-14: 72.3 · SMA20: $20.71 · SMA50: $19.46

6-Pillar Scorecard Institutional Category Breakdown (UTHR 2 – 4 TAK)

Columns: Metric · UTHR · TAK
1. Valuation Multiples TAK
Forward P/E 18.8x 12.7x
Trailing P/E 22.4x N/M
PEG Ratio 2.22x 0.47x
EV / Revenue 7.9x 2.6x
2. Growth & Scale TAK
Revenue Growth (YoY) +4.1% +6.7%
Earnings Growth (YoY) -20.3% -9.8%
TTM Revenue (USD) $3.19B $25.7B
Market Cap $25.3B $67.5B
3. Profitability & Quality UTHR
Gross Margin 86.3% 64.8%
Operating Margin 39.4% 16.6%
Net Profit Margin 38.6% 0.9%
Return on Equity (ROE) 19.1% 0.6%
4. Balance Sheet & Cash Flow TAK
Cash Generation (TTM) $867M $7.48B EBITDA
Cash Flow Margin 27.2% 29.1% EBITDA Mgn
Net Cash / Leverage $148.08 Book/Sh · 19.1% ROE $14.68 Book/Sh · 0.6% ROE
Dividend Yield None (0.00%) 2.92%
5. Options & Positioning UTHR
Options Structure Phase SURGE UNCLASSIFIED
Current IV / %ile 31.8% (6th %ile) 22.4% (5th %ile)
Put/Call OI Skew 0.75x (Call-Skewed) Thin ADR Chain
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat TAK
OpEx & R&D Intensity 46.9% of Rev ($1.49B) 48.2% of Rev ($12.4B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Scale & Operating Efficiency Moat
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: UTHR (4) vs TAK (6)
Institutional Metric UTHR TAK Criterion Row Edge
Market Capitalization
Scale
$25.3B $67.5B Larger Scale TAK
Trailing P/E Ratio
Valuation
22.4x N/M Lower Multiple UTHR
Forward P/E Ratio
Valuation
18.8x 12.7x Lower Multiple TAK
Revenue Growth (YoY)
Growth
+4.1% +6.7% Higher Growth TAK
Operating Margin (TTM)
Profitability
39.4% 16.6% Higher Margin UTHR
Net Profit Margin
Profitability
38.6% 0.9% Higher Margin UTHR
Return on Equity (ROE)
Capital Efficiency
19.1% 0.6% Higher ROE UTHR
52-Week Range Position
Momentum
81% ($456–$614) 97% ($14–$22) Stronger Trend TAK
Beta / 30D Volatility
Risk Regime
0.34β · 34% Vol -0.02β · 22% Vol Lower Realized Risk TAK
Unified Institutional Score
Composite Signal
44.8 / 100 (HOLD) 48.0 / 100 (HOLD) Higher Composite TAK
Trailing 12M Revenue (USD)
Operating Scale
$3.19B $25.7B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
86.3% 64.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.22x PEG · 7.9x EV/Rev 0.47x PEG · 2.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$867M ($148.08 Book/Sh · 19.1% ROE) $7.48B EBITDA ($14.68 Book/Sh · 0.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TAK +0.31 pp
UTHR: +9.58% · TAK: +9.89%
3M Horizon TAK +7.03 pp
UTHR: +12.72% · TAK: +19.75%
6M Horizon TAK +27.42 pp
UTHR: +3.03% · TAK: +30.45%
1Y Horizon TAK +25.42 pp
UTHR: +26.37% · TAK: +51.79%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on UTHR vs TAK. Trailing 12-month operating profitability (UTHR 39.4% vs TAK 16.6%) and valuation multiples (UTHR 18.8x vs TAK 12.7x Forward P/E) are benchmarked directly in Pillar 4 below.

UTHR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.19B
Gross Margin86.3%
Op. Margin39.4%
ROE / Fwd P/E19.1% · 18.8x
TAK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$25.7B
Gross Margin64.8%
Op. Margin16.6%
ROE / Fwd P/E0.6% · 12.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
UTHR SURGE
8d in phase · OBV ACCUMULATION
Current IV 31.8%
IV Percentile 6th %ile
Put/Call OI Skew 0.75x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact UTHR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TAK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 22.4%
IV Percentile 5th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TAK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
UTHR Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $25.3B market capitalization and 39.4% operating margin.
OpEx & R&D Reinvestment 46.9% of Rev ($1.49B)
90D Engineering Disclosures 0 Published
TAK Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $67.5B market capitalization and 16.6% operating margin.
OpEx & R&D Reinvestment 48.2% of Rev ($12.4B)
90D Engineering Disclosures 0 Published

Investor FAQ UTHR vs TAK Key Questions & Quantitative Answers

As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over United Therapeutics Corp (UTHR) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). UTHR carries a Unified Composite Score of 44.8/100 (HOLD) at $584.19 (18.8x Forward P/E, 39.4% operating margin), whereas TAK carries 48.0/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin). Technically, UTHR sits in a Markup phase (RSI 54.6, SURGE options structure) and TAK sits in a Markup phase (RSI 72.3, UNCLASSIFIED options structure).

TAK leads the Growth & Scale pillar: UTHR posts +4.1% YoY revenue growth and -20.3% YoY earnings growth on $3.19B TTM revenue (86.3% gross margin, 39.4% operating margin), compared with TAK at +6.7% YoY revenue growth and -9.8% YoY earnings growth on $25.7B TTM revenue (64.8% gross margin, 16.6% operating margin). On trailing 12-month operating scale, UTHR generates $3.19B in USD-normalized revenue versus $25.7B for TAK. In operating R&D and SG&A reinvestment, UTHR deploys 46.9% of Rev ($1.49B) (0 90-day corporate R&D disclosures) versus 48.2% of Rev ($12.4B) (0 disclosures) for TAK.

TAK screens cheaper on headline valuation multiples. UTHR trades at 18.8x Forward P/E, 22.4x Trailing P/E, 2.22x PEG, and 7.9x EV/Revenue (27.2% FCF margin), whereas TAK trades at 12.7x Forward P/E, N/M Trailing P/E, 0.47x PEG, and 2.6x EV/Revenue (29.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against UTHR (19.1% ROE) versus TAK (0.6% ROE) capital efficiency.

In options market volatility and institutional positioning, UTHR carries 31.8% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.75x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (0.34β · 34% Vol realized risk). By comparison, TAK carries 22.4% implied volatility (5th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 22% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.